Your Article Summary
See Latest ArticlesDivergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma
Cancer, 06/29/09
Anderson WF et al. - In a trial to discern the timing and/or age of exposure for cutaneous malignant melanomas (CMM), current results were consistent with a divergent and age-dependent solar hypothesis for CMM. Early-onset melanomas may represent gene-sun exposure interactions that occur early in life among susceptible individuals. Late-onset melanomas may reflect accumulated, lifelong sun exposure in comparatively less susceptible individuals.
Methods- Effect of aging on CMM incidence were systematically examined in data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.
- Standard descriptive epidemiology was supplemented with mathematical models.
- Impact of advancing age on CMM incidence was assessed by sex, histopathologic classification (superficial spreading melanoma [SSM] or lentigo maligna melanoma [LMM]), and anatomic site (face, head, and neck [FHN] or lower extremity [LE]).
- Sex, histopathology, and anatomic site were age-specific effect modifiers for CMM that indicated divergent (bimodal) early-onset and late-onset cancer pathways.
- Early-onset melanomas were associated predominantly with women, SSM, and LE.
- Late-onset melanomas were correlated with men, LMM, and FHN.
- Early- and late-onset melanoma populations were confirmed with age-period-cohort models that were adjusted for period and cohort effects.
- 2-component mixture models also fit the data better than a single cancer population.
Related Articles
Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma
Modern Pathology, 10/23/09
Relevance Score: 81%
Metastatic cutaneous malignant melanoma: Spectrum of imaging findings and the role of multimodality imaging
Journal of Medical Imaging and Radiation Oncology (JMIRO), 10/05/09
Relevance Score: 81%
Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies
Expert Review of Anticancer Therapy, 11/12/09
Relevance Score: 80%
Case of cutaneous malignant melanoma surviving 16 years with late recurrence
Journal of Dermatology, 11/04/09
Relevance Score: 79%
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09
Relevance Score: 69%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Pigmented Epithelioid Melanocytoma: Favorable Outcome After 5-year Follow-up
American Journal of Surgical Pathology , 12/08/09
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
International Journal of Cancer, 12/07/09
Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion
International Journal of Cancer, 12/07/09